You are about to leave the Nuvalent website.

Nuvalent does not endorse or take responsibility for any information or statements made on external sites.

Do you wish to continue?

Our Team

Henry Pelish, PhD

Henry is a multidisciplinary scientist skilled in cancer biology, chemical biology and organic synthesis. He contributed to the creation of Nuvalent and joined full-time in 2018. 

Henry’s career has spanned multiple industry and academic appointments. Prior to joining Nuvalent, Henry was a group leader in the laboratory of Professor Matthew Shair at Harvard University. In that role, he built and led a team that discovered a new target, mechanism of action and therapeutic opportunity for treatment of acute myeloid leukemia. In parallel, he spearheaded a drug discovery program that culminated in a licensing deal and research agreement between Harvard and Merck in 2016, and subsequently served as a member of the Harvard-Merck Joint Research Committee.

Henry earned a PhD in Chemistry from Harvard University and is an avid runner and swimmer.